Publication:
Comparative trial of silver nanoparticle gel and 1% clindamycin gel when use in combination with 2.5% benzoyl peroxide in patients with moderate acne vulgaris

dc.contributor.authorJurairattanaporn N.
dc.contributor.authorChalermchai T.
dc.contributor.authorOphaswongse S.
dc.contributor.authorUdompataikul M.
dc.date.accessioned2021-04-05T03:22:56Z
dc.date.available2021-04-05T03:22:56Z
dc.date.issued2017
dc.date.issuedBE2560
dc.description.abstractBackground: Treatments of acne vulgaris commonly use antimicrobials and comedolytic agents. Considering bacterial resistance to topical antibiotics, the alternative treatment such as silver manufactured into nanoparticle receives an atten­tion. Silver nanoparticle has an antibacterial effect against Propionibacterium acnes and anti-inflammation. Clinical study of silver nanoparticle gel for the treatment of acne vulgaris is limited. Objective: To compare the efficacy and safety between silver nanoparticle gel and 1% clindamycin gel both combine with 2.5% benzoyl peroxide for the treatment of moderate severity of acne vulgaris. Material and Method: This was an experimental, double-blinded, randomized-controlled study. Sixty-four moderately severe acne patients were enrolled. They were randomized to receive either silver nanoparticle gel with 2.5% benzoyl peroxide or clindamycin gel with 2.5% benzoyl peroxide (32 patients each). The clinical outcomes were evaluated for inflammatory and non-inflammatory acne count, acne redness, the patients’ satisfaction and patients’ Dermatology Life Quality Index (DLQI) at the baseline, 2, 4, 6 and 8-week visit. Results: After 8 weeks of follow-up period, the average mean percent change from the baseline of non-inflammatory and inflammatory acne counts were gradually declined in both silver nanoparticle and clindamycin group. At the study endpoint (8-week visit), average mean percent change from the baseline of inflammatory acne count was slightly better reduction in silver nanoparticle group (79.7%) than clindamycin group (72.6%) with no significant difference (p = 0.18). The average mean percent change from the baseline of non-inflammatory acne count reduction was also no difference from silver nanoparticle and clindamycin group (61.1% and 66.8% respectively, p = 0.22). For clinical erythema score and Mexameter erythema index to evaluate acne redness were no statistical difference between the 2 groups. Moreover, the patients’ satisfaction to study medication and their quality of life of patients (DLQI score) were reported with better improvement from the baseline in both groups but there was no statistical significant difference. Except for average mean, patients’ satisfaction to acne severity at 6-week visit showed that silver nanoparticle group had better satisfaction score than clindamycin group (4.6±0.6 vs. 4.2±0.6) with statistical significance (p = 0.01). Common adverse effects were skin dryness (28.1%) and skin irritation (4.7%) which might be caused by 2.5% benzoyl peroxide. There was no adverse effect for silver nanoparticle gel from the present study. Conclusion: Silver nanoparticle gel is effective with good safety profile for the treatment of acne vulgaris. The present study demonstrated that there were no clinical significant differences between silver nanoparticle gel and clindamycin gel for the treatment of moderate severity of acne vulgaris when use in combination with 2.5% benzoyl peroxide. The clinical application as alternative treatment for acne is advised. © 2017, Medical Association of Thailand. All rights reserved.
dc.format.mimetypeapplication/pdf
dc.identifier.citationJournal of the Medical Association of Thailand. Vol 100, No.1 (2017), p.78-85
dc.identifier.issn1252208
dc.identifier.other2-s2.0-85018692835
dc.identifier.urihttps://hdl.handle.net/20.500.14740/4610
dc.rights.holderScopus
dc.subject.otherBenzoyl peroxide
dc.subject.otherClindamycin
dc.subject.otherSilver nanoparticle
dc.subject.otherAcne vulgaris
dc.subject.otherAdult
dc.subject.otherArticle
dc.subject.otherClinical outcome
dc.subject.otherComparative study
dc.subject.otherControlled study
dc.subject.otherDermatology Life Quality Index
dc.subject.otherDouble blind procedure
dc.subject.otherDrug dosage form comparison
dc.subject.otherDrug efficacy
dc.subject.otherDrug safety
dc.subject.otherDry skin
dc.subject.otherFemale
dc.subject.otherHuman
dc.subject.otherMajor clinical study
dc.subject.otherMale
dc.subject.otherMiddle aged
dc.subject.otherQuality of life
dc.subject.otherRandomized controlled trial
dc.subject.otherSkin irritation
dc.titleComparative trial of silver nanoparticle gel and 1% clindamycin gel when use in combination with 2.5% benzoyl peroxide in patients with moderate acne vulgaris
dc.typeArticle
dspace.entity.typePublication
swu.datasource.scopushttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85018692835&partnerID=40&md5=598c733e9cb20e52db6043d8266bd501

Files